Aurinia Pharmaceuticals Inc. last reported quarterly results on Oct 30, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $83.7 million (+13.9% year over year) and diluted EPS of $0.23. It usually reports 30–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 25, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 26, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 30–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 30, 2026
30 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
84
+13.9%
|
32
+0.5%
|
0.23
+0.0%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
83
+18.9%
|
37
+73.9%
|
0.28
+75.0%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
78
+24.4%
|
34
+47.2%
|
0.25
+56.2%
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
77
+28.8%
|
211
+14651.2%
|
1.53
+15200.0%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
73
+8.4%
|
32
+119.9%
|
0.23
+130.0%
|
|
Jul 31, 2025
31 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
70
+22.4%
|
22
+2879.6%
|
0.16
+1500.0%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
62
+24.2%
|
23
+317.2%
|
0.16
+328.6%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
60
+32.8%
|
1
+105.3%
|
0.01
+105.3%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AUPH (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Edmonton, Alberta, Canada
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1600620
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.